You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 9 No. 3, September 1963 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (37)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Muscle Biopsy Experience in Myasthenia Gravis

GERALD M. FENICHEL, MD; G. MILTON SHY, MD

Arch Neurol. 1963;9(3):237-243.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

The histopathologic changes of skeletal muscle in patients with myasthenia gravis have been well documented in many large autopsy series. More recently, intravital staining and electron microscopy have demonstrated tissue alterations in the presynaptic portion of the neuromuscular junction.

The present study is designed to evaluate the usefulness of the muscle biopsy as a diagnostic aid in myasthenia gravis. In addition, the significance of some histological changes previously described will be reconsidered and discussed.

Methods

Muscle specimens from 37 patients with myasthenia gravis were examined in the study. The criteria for diagnosis were an appropriate history of muscle weakness and fatigue related to exercise and a response to anticholinesterase medication. No second disorder was present in any of these patients that might affect skeletal muscle. Specimens from patients with myasthenic syndromes secondary to carcinoma of the lung or thyrotoxicosis were excluded. Tables 1-3 summarize clinical information pertinent to the . . . [Full Text PDF of this Article]


Author Affiliations

BETHESDA, MD

US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Institute of Neurological Diseases and Blindness, Medical Neurology Branch.


Footnotes

Submitted for publication April 20, 1963; accepted June 8, 1963.

Work done as Clinical Associate, MN, NINDB (Dr. Fenichel).

Present address: Professor and Chairman, Department of Neurology, University of Pennsylvania, 34th and Spruce St, Philadelphia 4, (Dr. Shy).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1963 American Medical Association. All Rights Reserved.